News Revance Therapeutics, Inc.

Equities

RVNC

US7613301099

Real-time Estimate Cboe BZX Other stock markets 02:05:55 2024-04-26 pm EDT			5-day change	1st Jan Change
3.475 ^USD	+5.62%		-7.97%	-60.42%

01:36pm	AbbVie raises annual profit forecast on strong Skyrizi sales	RE
Apr. 12	Revance Therapeutics, Inc. to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

AbbVie raises annual profit forecast on strong Skyrizi sales	07:36am	RE
Revance to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting	Apr. 15	AQ
Northern District Of California Grants Motion To Dismiss Putative Class Action Against Biotech Company And Executives	Apr. 15	AQ
Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting	Apr. 12	BU
Revance Therapeutics, Inc. to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting	Apr. 12	CI
Revance Reports Inducement Grants under Nasdaq Listing Rule 5635(4)	Mar. 28	AQ
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Mar. 27	BU
Transcript : Revance Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 09:30 AM	Mar. 12
North American Morning Briefing: Stock Futures Fall With Investor Focus on Inflation Data	Mar. 11	DJ
Court Finds Access To Botox Trade Secrets And Similarity Of Competitor Product Supported Inference Of Trade Secrets Misappropriation	Mar. 07	AQ
Revance Therapeutics Prices $100 Million Public Offering	Mar. 04	MT
Revance Announces Pricing of $100.0 Million Public Offering of Common Stock	Mar. 04	BU
Revance Announces Proposed Public Offering of Common Stock	Mar. 04	BU
Goldman Sachs Adjusts Price Target on Revance Therapeutics to $9 From $8, Maintains Neutral Rating	Mar. 01	MT
Needham Cuts Price Target on Revance Therapeutics to $18 From $20, Maintains Buy Rating	Feb. 29	MT
Piper Sandler Cuts Price Target on Revance Therapeutics to $20 From $42, Maintains Overweight Rating	Feb. 29	MT
Transcript : Revance Therapeutics, Inc., Q4 2023 Earnings Call, Feb 28, 2024	Feb. 28
Earnings Flash (RVNC) REVANCE THERAPEUTICS Posts Q4 Revenue $69.8M	Feb. 28	MT
Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update	Feb. 28	BU
Revance Therapeutics, Inc. Provides Revenue Guidance for the Year 2024	Feb. 28	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Revance Therapeutics, Inc.

Equities

RVNC

US7613301099

Summary

Filters